You are browsing the Hong Kong website, Regulated by Hong Kong SFC (CE number: BJA907). Investment is risky and you must be cautious when entering the market.
小智港股覆盤 | 7月4日

今日,港股三大指數漲跌互現。截止收盤,恆生指數跌0.13%,報21830點。國企指數跌0.25%,報7647點。恆生科技指數漲0.28%,報4884點。市場約609只個股上漲,1093只個股下跌。成交額突破1314.45億港幣,和昨天同期相比下跌13.22%。南下資金淨流入12.1億港幣。

領跌板塊

盤面上,CRO板塊全線走強。泰格醫藥、昭衍新藥、藥明生物等多股漲超8%;金斯瑞生物科技、藥明康德等多股漲超7%。昭衍新藥漲超10%領漲CRO概念股,藥品管理法實施條例大修,多角度鼓勵藥物創新;金斯瑞生物科技擬2.6億元收購鎮江市科技園開發區物業,擬用作集團工廠以擴大生物製劑產品產能;藥明康德:第二季度激勵對象行權且完成股份過戶登記的股票期權數共計97.82萬股。

板塊行情

生物科技板塊暴漲。榮昌生物-B漲超15%;再鼎醫藥-B、康方生物-B等多股漲超14%;百濟神州漲超10%;信達生物漲超8%。交銀國際維持康方生物-B買入評級,目標價續看30.66港元;百濟神州根據股份獎勵計劃發行69.5萬股;信達生物漲近4%,達伯舒®聯合化療用於一線治療胃及胃食管交界處腺癌的新適應症上市申請獲國家藥監局批準。

板塊行情

醫療設備板塊集體拉昇。微創機器人-B漲超18%;百心安-B、微創醫療等多股漲超8%;先瑞達醫療-B漲超6%;愛康醫療漲超5%。微創機器人-B拉漲20%,機構指公司商業化放量進程已箭在弦上;百心安-B(2185.HK)升超5%創新高,市值近160億港元;微創醫療:微創腦科學發售價將爲每股24.64港元。

板塊行情

電子板塊跌幅居前。昇華蘭德跌超11%;融科控股跌超10%;信懇智能跌超9%;光控精技跌超8%;通達宏泰跌超6%

板塊行情

商業服務板塊跌幅居前。長城匯理跌超14%;新華通訊頻媒、中國唐商等多股跌超10%;EPRINT集團跌超9%;雅生活服務跌超8%

板塊行情

化學制品板塊走低。雋泰控股跌超7%;世紀陽光跌超6%;東嶽集團、中國旭陽集團等多股跌超5%;環球新材國際跌超4%。中國旭陽集團再度反彈2.29%,附屬公司與樂亭華陽訂立租賃協議。

板塊行情

uSMART智能寫手的信息、數據均來自媒體公開報道,智能寫手不能保證其完全準確,內容僅供參考,不構成投資建議。

Follow us
Find us on Facebook, Twitter , Instagram, and YouTube or frequent updates on all things investing.Have a financial topic you would like to discuss? Head over to the uSMART Community to share your thoughts and insights about the market! Click the picture below to download and explore uSMART app!
Disclaimers
uSmart Securities Limited (“uSmart”) is based on its internal research and public third party information in preparation of this article. Although uSmart uses its best endeavours to ensure the content of this article is accurate, uSmart does not guarantee the accuracy, timeliness or completeness of the information of this article and is not responsible for any views/opinions/comments in this article. Opinions, forecasts and estimations reflect uSmart’s assessment as of the date of this article and are subject to change. uSmart has no obligation to notify you or anyone of any such changes. You must make independent analysis and judgment on any matters involved in this article. uSmart and any directors, officers, employees or agents of uSmart will not be liable for any loss or damage suffered by any person in reliance on any representation or omission in the content of this article. The content of this article is for reference only. It does not constitute an offer, solicitation, recommendation, opinion or guarantee of any securities, financial products or instruments.The content of the article is for reference only and does not constitute any offer, solicitation, recommendation, opinion or guarantee of any securities, virtual assets, financial products or instruments. Regulatory authorities may restrict the trading of virtual asset-related ETFs to only investors who meet specified requirements.
Investment involves risks and the value and income from securities may rise or fall. Past performance is not indicative of future performance.
uSMART
Wealth Growth Made Easy
Open Account